Literature DB >> 19815832

Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study.

Laurent Garderet1, Ladan Kobari, Christelle Mazurier, Caroline De Witte, Marie-Catherine Giarratana, Christine Pérot, Norbert Claude Gorin, Hélène Lapillonne, Luc Douay.   

Abstract

BACKGROUND: Anemia is a characteristic of myelodysplastic syndromes, such as the rare 5q- syndrome, but its mechanism remains unclear. In particular, data are lacking on the terminal phase of differentiation of erythroid cells (enucleation) in myelodysplastic syndromes. DESIGN AND METHODS: We used a previously published culture model to generate mature red blood cells in vitro from human hematopoietic progenitor cells in order to study the pathophysiology of the 5q- syndrome. Our model enables analysis of cell proliferation and differentiation at a single cell level and determination of the enucleation capacity of erythroid precursors.
RESULTS: The erythroid commitment of 5q(del) clones was not altered and their terminal differentiation capacity was preserved since they achieved final erythroid maturation (enucleation stage). The drop in red blood cell production was secondary to the decrease in the erythroid progenitor cell pool and to impaired proliferative capacity. RPS14 gene haploinsufficiency was related to defective erythroid proliferation but not to differentiation capacity.
CONCLUSIONS: The 5q- syndrome should be considered a quantitative rather than qualitative bone marrow defect. This observation might open the way to new therapeutic concepts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19815832      PMCID: PMC2833069          DOI: 10.3324/haematol.2009.012773

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  34 in total

1.  Abnormal stromal cells in myelodysplastic syndromes: genomics presents further evidence.

Authors:  Hector Mayani
Journal:  Leuk Res       Date:  2006-11-17       Impact factor: 3.156

2.  Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis.

Authors:  Mario Cazzola
Journal:  Haematologica       Date:  2008-07       Impact factor: 9.941

3.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

Review 4.  Supportive care, growth factors, and new therapies in myelodysplastic syndromes.

Authors:  Eva Hellström-Lindberg; Luca Malcovati
Journal:  Blood Rev       Date:  2008-02-20       Impact factor: 8.250

5.  Ribosomal protein S19 deficiency leads to reduced proliferation and increased apoptosis but does not affect terminal erythroid differentiation in a cell line model of Diamond-Blackfan anemia.

Authors:  Koich Miyake; Taiju Utsugisawa; Johan Flygare; Thomas Kiefer; Isao Hamaguchi; Johan Richter; Stefan Karlsson
Journal:  Stem Cells       Date:  2007-10-25       Impact factor: 6.277

6.  Bone marrow mononuclear cells of MDS patients are characterized by in vitro proliferation and increased apoptosis independently of stromal interactions.

Authors:  Lambert F R Span; Eugenie Rutten; Anita Gemmink; Jan B M Boezeman; Reinier A P Raymakers; Theo de Witte
Journal:  Leuk Res       Date:  2007-07-30       Impact factor: 3.156

7.  Impaired differentiation and apoptosis of hematopoietic precursors in a mouse model of myelodysplastic syndrome.

Authors:  Chul Won Choi; Yang Jo Chung; Christopher Slape; Peter D Aplan
Journal:  Haematologica       Date:  2008-07-04       Impact factor: 9.941

Review 8.  Myelodysplastic syndromes.

Authors:  Stephen D Nimer
Journal:  Blood       Date:  2008-05-15       Impact factor: 22.113

9.  An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.

Authors:  Benjamin L Ebert; Naomi Galili; Pablo Tamayo; Jocelyn Bosco; Raymond Mak; Jennifer Pretz; Shyam Tanguturi; Christine Ladd-Acosta; Richard Stone; Todd R Golub; Azra Raza
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

10.  Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.

Authors:  Benjamin L Ebert; Jennifer Pretz; Jocelyn Bosco; Cindy Y Chang; Pablo Tamayo; Naomi Galili; Azra Raza; David E Root; Eyal Attar; Steven R Ellis; Todd R Golub
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

View more
  5 in total

1.  Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.

Authors:  Martin Jädersten
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

2.  STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells.

Authors:  Jared Klarquist; Cassandra M Hennies; Maria A Lehn; Rachel A Reboulet; Sonia Feau; Edith M Janssen
Journal:  J Immunol       Date:  2014-11-10       Impact factor: 5.422

3.  Caspase-3 is involved in the signalling in erythroid differentiation by targeting late progenitors.

Authors:  Daniela Boehm; Christelle Mazurier; Marie-Catherine Giarratana; Dhouha Darghouth; Anne-Marie Faussat; Laurence Harmand; Luc Douay
Journal:  PLoS One       Date:  2013-05-02       Impact factor: 3.240

Review 4.  From Erythroblasts to Mature Red Blood Cells: Organelle Clearance in Mammals.

Authors:  Martina Moras; Sophie D Lefevre; Mariano A Ostuni
Journal:  Front Physiol       Date:  2017-12-19       Impact factor: 4.566

5.  Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.

Authors:  Ota Fuchs
Journal:  Leuk Res Treatment       Date:  2012-02-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.